Summit Therapeutics signs agreement to sell phase III asset ridinilazole to Biossil

Summit Therapeutics Inc., a biopharmaceutical oncology company, announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigational phase III precision antibiotic

To access the full article, please log in or subscribe.